Symbol | Exchange | Currency |
|---|
Cocrystal Pharma Inc (NASDAQ: COCP) announces that its SARS-CoV-2 3CL protease lead CDI-45205 and several analogs showed potent in vitro activity against the SARS-CoV-2 Delta...
US biotechnology company Cocrystal Pharma (COCP) has been selected to join the Russell Microcap Index.The move is effective June 28, 2021, after the U.S
Shares of Cocrystal Pharma, Inc. (NASDAQ:COCP) surged 18.6% after the company announced plans to advance its coronavirus program.Shares of Compugen Ltd. (NASDAQ:CGEN) gained...
Alpha Pro Tech (NYSE:APT), which is a manufacturer of masks and containment gowns, was up 2.86, or 40%, to 10.00, on 19 million shares on Tuesday. This stock went in Jan from...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Neutral | Neutral | Buy | Neutral | Strong Sell |
| Technical Indicators | Strong Sell | Strong Sell | Sell | Buy | Sell |
| Summary | Sell | Sell | Neutral | Neutral | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,715.60 | 2,733.20 | 2,710.90 | -6.3 | -0.23% | 1.59M | NASDAQ | |||
| 358.32 | 365.52 | 356.74 | -14.96 | -4.01% | 33.41M | NASDAQ | |||
| 25.75 | 26.29 | 25.74 | -0.14 | -0.54% | 406.45K | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 13.73 | 14.10 | 13.70 | +0.34 | +2.54% | 3.95M | NYSE | |||
| 21.81 | 21.99 | 21.59 | +0.47 | +2.20% | 16.42M | NYSE | |||
| 57.05 | 57.25 | 56.86 | +0.31 | +0.55% | 9.60M | NYSE | |||
| 27.74 | 28.90 | 26.87 | -0.25 | -0.89% | 11.47M | NASDAQ | |||
| 6.54 | 6.68 | 6.39 | +0.270 | +4.31% | 22.83M | NYSE | |||
| 64.77 | 65.86 | 63.24 | +3.05 | +4.94% | 2.41M | NYSE | |||
| 19.92 | 20.82 | 19.88 | -0.59 | -2.88% | 11.70M | NYSE | |||
| 42.79 | 43.30 | 42.62 | -0.27 | -0.63% | 29.02M | NYSE | |||
| 1.15 | 1.17 | 1.11 | +0.0100 | +0.88% | 6.01M | NYSE | |||
| 0.623 | 0.00 | 0.00 | +0.0030 | +0.48% | 1.13M | NYSE | |||
| 76.93 | 77.92 | 76.81 | -1.40 | -1.79% | 11.58M | NYSE |
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.
